These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3867805)

  • 1. Should hyperlipemia of renal failure be treated?
    Ritz E; Augustin J; Bommer J; Gnasso A; Haberbosch W
    Kidney Int Suppl; 1985 Dec; 17():S84-7. PubMed ID: 3867805
    [No Abstract]   [Full Text] [Related]  

  • 2. Atherosclerosis in patients undergoing maintenance hemodialysis.
    Bagdade JD
    Kidney Int Suppl; 1975 Feb; (3):370-2. PubMed ID: 169427
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dyslipidemia and accelerated atherosclerosis in chronic uremia: a probably decreasing pathology, due to nutritional studies and better dietary guidelines].
    Campanacci L; Guabnieri GF; Toigo G; Huber W; Legnani F; Moracchiello M; Tesio F; Raimondi A
    G Clin Med; 1978; 59(7-8):318-31. PubMed ID: 216602
    [No Abstract]   [Full Text] [Related]  

  • 4. Atherosclerotic complications in chronic renal failure: epidemiology and predictive factors.
    Jungers P; Nguyen Khoa T; Joly D; Choukroun G; Witko-Sarsat V; Massy ZA
    Adv Nephrol Necker Hosp; 2000; 30():177-99. PubMed ID: 11068642
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid metabolism in uremia and the effects of dialysate glucose and oral androgen therapy.
    Dombeck DH; Lindholm DD; Vieira JA
    Trans Am Soc Artif Intern Organs; 1973; 19():150-3. PubMed ID: 4352987
    [No Abstract]   [Full Text] [Related]  

  • 6. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation.
    Nishizawa Y; Shoji T; Kawagishi T; Morii H
    Kidney Int Suppl; 1997 Nov; 62():S90-2. PubMed ID: 9350691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrophosphate and diphosphonates in calcium metabolism and their possible role in renal failure.
    Russell RG; Bisaz S; Fleisch H
    Arch Intern Med; 1969 Nov; 124(5):571-7. PubMed ID: 4310762
    [No Abstract]   [Full Text] [Related]  

  • 8. Disorders of carbohydrate and lipid metabolism in uremia.
    Bagdade
    Nephron; 1975; 14(2):153-62. PubMed ID: 1093054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kidney in health and disease XXIII. The pathophysiology of uremia.
    Knochel JP
    Hosp Pract (Off Ed); 1981 Nov; 16(11):65-76. PubMed ID: 6797927
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of renal osteodystrophy with 25-hydroxycholecalciferol.
    DeLuca HF; Avioli LV
    Arch Intern Med; 1970 Nov; 126(5):896-9. PubMed ID: 4319937
    [No Abstract]   [Full Text] [Related]  

  • 11. [Behavior of uremic hyperlipemia and disturbances of glucose tolerance under chronic intermittent hemodialysis treatment].
    Hübner W; Diemer A; Freiberg J
    Med Welt; 1972 Oct; 23(41):1415-7. PubMed ID: 4648587
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chronic renal insufficiency and hyperlipemia].
    Rocha PP; Lazera ES; Sampaio JC; Amancio A
    Arq Bras Cardiol; 1979 Apr; 32(4):247-9. PubMed ID: 508107
    [No Abstract]   [Full Text] [Related]  

  • 13. The nature of vitamin D resistance in experimental uremia.
    Kimberg DV; Baerg RD; Gershon E
    Arch Intern Med; 1970 Nov; 126(5):891-5. PubMed ID: 4319936
    [No Abstract]   [Full Text] [Related]  

  • 14. Atherosclerosis and uremic retention solutes.
    Hörl WH; Cohen JJ; Harrington JT; Madias NE; Zusman CJ
    Kidney Int; 2004 Oct; 66(4):1719-31. PubMed ID: 15458484
    [No Abstract]   [Full Text] [Related]  

  • 15. Disorders of blood-lipids in renal disease.
    Cramp DG; Moorhead JF; Wills MR
    Lancet; 1975 Mar; 1(7908):672-3. PubMed ID: 47091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipid anomalies during renal insufficiency: consequences on the progression of renal insufficiency and cardiovascular risk].
    Moulin B
    Nephrologie; 2000; 21(7):339-41. PubMed ID: 11200605
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hyperlipemia as cardiovascular risk factor in childhood].
    Sarriá A; Moreno L; Lázaro A; Mur M; Bueno M
    An Esp Pediatr; 1993 Oct; 39 Suppl 55():149-52. PubMed ID: 8291792
    [No Abstract]   [Full Text] [Related]  

  • 18. [Relative concentration of VLDL C-apolipoproteins in the hyperlipoproteinaemia of haemodialysis-treated chronic renal failure (author's transl)].
    Dewailly P; Dedonder E; Fruchart JC; Sezille G; Jaillard J
    Diabete Metab; 1980 Mar; 6(1):13-6. PubMed ID: 7371894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral inhibitors of the immune response in uremia. III. The immunosuppressive factor of uremic rat serum is a very low density lipoprotein.
    Raska K; Morrison AB; Raskova J
    Lab Invest; 1980 Jun; 42(6):636-42. PubMed ID: 6446621
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone disease in uremia.
    Coburn JW
    Henry Ford Hosp Med J; 1983; 31(4):217-20. PubMed ID: 6674267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.